Barriers and solutions for CAR-T therapy in solid tumors



Summary

CAR-T cell therapy, a revolutionary cancer treatment, faces significant barriers in solid tumors compared to blood cancers. These hurdles include poor CAR-T cell trafficking to the tumor site, an immunosuppressive tumor microenvironment (TME) hindering CAR-T cell activity, and limited identification of specific, safe tumor-associated antigens.

Solutions being explored involve enhancing CAR-T cell homing through modifications like chemokine receptor expression, overcoming TME suppression using checkpoint inhibitors or TME-modifying agents, and developing more selective CAR targets with improved safety profiles, such as combinatorial antigen targeting and logic-gated CARs. Overcoming these challenges is crucial for expanding the efficacy of CAR-T therapy to a broader range of cancers.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!